Health Dictionary Find a Doctor

Moyamoya disease

For patient information, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Overview

Moyamoya syndrome is a disease in which certain arteries in the brain are constricted. Blood flow is blocked by the constriction, and also by blood clots (thrombosis).[1]The blood vessels develop collateral circulation around the blocked vessels to compensate for the blockage, but the collateral vessels are small, weak, and prone to hemorrhage, aneurysm and thrombosis. On X-rays, these collateral vessels have the appearance of a “puff of smoke” (“もやもや (moyamoya)” in Japanese).[1] The disease causes constrictions primarily in the internal carotid artery, which travels from the neck up inside the skull just under the brain in the cavernous sinus. At the Circle of Willis, the internal carotid artery flows into the middle cerebral artery, which continues into the brain, and the anterior cerebral artery, which is part of the Circle of Willis. Moyamoya disease often extends to the middle and anterior cerebral arteries.[1] When the internal carotid artery becomes completely blocked, the fine collateral circulation that it supplies is obliterated. Patients often survive on the collateral circulation from the back (posterior) of the Circle of Willis, from the basilar artery.[1]

Causes

The condition is believed to be hereditary and linked to q25.3, on chromosome 17. Moyamoya can be either congenital or acquired. Patients with Down syndrome, neurofibromatosis, or sickle cell disease can develop moyamoya malformations. It is more common in women than in men, although about a third of those affected are male.[2] Brain radiation therapy in children with neurofibromatosis increases the risk of its development.

Risk Factors

Women have a higher risk of recurrent stroke and may be experiencing a distinct underlying pathophysiology compared to patients from Japan.

CT

The diagnosis is initially suggested by CT, MRI, or angiogram. In fact, the name derives from its angiographic image; the “puff of smoke,” which is how moyamoya loosely translates from Japanese, refers to the appearance of multiple compensatorily dilated striate vessels seen on angiography. Contrast-enhanced T1-weighted images are better than FLAIR images for depicting the leptomeningeal ivy sign in moyamoya disease.

MRI

MRI and MRA should be performed for the diagnosis and follow-up of moyamoya disease. Diffusion-weighted imaging can also be used for following the clinical course of children with moyamoya disease, in whom new focal deficits are highly suspicious of new infarcts.

Other Imaging Findings

Often nuclear medicine studies such as SPECT (single photon emission computerized tomography) are used to demonstrate the decreased blood and oxygen supply to areas of the brain involved with moyamoya disease. Conventional angiography provided the conclusive diagnosis of moyamoya disease in most cases and should be performed before any surgical considerations.

Treatment

Medical Therapy

Drugs such as antiplatelet agents (e.g., aspirin) are usually given to prevent clots, but surgery is usually recommended. Since moyamoya tends to affect only the internal carotid artery and nearby sections of the adjacent anterior and middle cerebral arteries, surgeons can direct other arteries, such as the external carotid artery or the superficial temporal artery to replace its circulation. The arteries are either sewn directly into the brain circulation, or placed on the surface of the brain to reestablish new circulation after a few weeks. Although there is a 4% risk of stroke soon (30 days) after surgery, there is a 96% probability of remaining stroke-free over the next 5 years.[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 Moyamoya Disease and Moyamoya Syndrome, R. Michael Scott and Edward R. Smith, New England Journal of Medicine, 360:1226-1237, March 19, 2009
  2. Kuriyama S, Kusaka Y, Fujimura M; et al. (2008). “Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey”. Stroke. 39 (1): 42–7. doi:10.1161/STROKEAHA.107.490714. PMID 18048855.

Template:WH Template:WS

Historical Perspective

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Classification

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Pathophysiology

The condition is believed to be hereditary and linked to q25.3, on chromosome 17. They have a higher risk of recurrent stroke and may be experiencing a distinct underlying pathophysiology compared to patients from Japan. Data suggest a potential benefit with surgery if early diagnosis is made.[1] The pathogenesis of moyamoya disease is unknown.

Once it begins, the process of blockage (vascular occlusion) tends to continue despite any known medical management. In some people this leads to repeated strokes and severe functional impairment or even death. In others, this blockage may not cause any symptoms.

Moyamoya can be either congenital or acquired. Patients with Down syndrome, neurofibromatosis, or sickle cell disease can develop moyamoya malformations. It is more common in women than in men, although about a third of those affected are male.[2] Brain radiation therapy in children with neurofibromatosis increases the risk of its development.

The constrictions of the arteries in moyamoya disease are unlike the constrictions in atherosclerosis. In atherosclerosis, the inner layer (lumen) of the arteries suffers an immune reaction, fills with inflammatory cells, and accumulates fatty cells and debris. In moyamoya, the inner layer of the carotid artery overgrows inward to constrict the artery, and the artery also fills with blood clots, which cause strokes.[3]

References

  1. Hallemeier C, Rich K, Brubb R, Chicoine M, Moran C, Cross D, Zipfel G, Dacey R, Derdeyn (2006). “Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey”. Stroke. 37 (6): 1490–1496. doi:10.1161/01.STR.0000221787.70503.ca. PMID 16645133.
  2. Kuriyama S, Kusaka Y, Fujimura M; et al. (2008). “Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey”. Stroke. 39 (1): 42–7. doi:10.1161/STROKEAHA.107.490714. PMID 18048855.
  3. Moyamoya Disease and Moyamoya Syndrome, R. Michael Scott and Edward R. Smith, New England Journal of Medicine, 360:1226-1237, March 19, 2009

Template:WH Template:WS

Causes

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Overview

The condition is believed to be hereditary and linked to q25.3, on chromosome 17. Moyamoya can be either congenital or acquired. Patients with Down syndrome, neurofibromatosis, or sickle cell disease can develop moyamoya malformations. It is more common in women than in men, although about a third of those affected are male.[1] Brain radiation therapy in children with neurofibromatosis increases the risk of its development.

References

  1. Kuriyama S, Kusaka Y, Fujimura M; et al. (2008). “Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey”. Stroke. 39 (1): 42–7. doi:10.1161/STROKEAHA.107.490714. PMID 18048855.

Template:WH Template:WS

Differentiating Moyamoya Disease from other Diseases

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Epidemiology and Demographics

Incidence

In Japan the overall incidence is higher (0.35 per 100,000).[1] It is more common in women than in men, although about a third of those affected are male .[2]

Age

It is a disease that tends to affect children and adults in the third to fourth decades of life. In children it tends to cause strokes or seizures. In adults it tends to cause strokes or bleeding.

Gender

Women frequently experience transient ischemic attacks (TIA), cerebral hemorrhage or no symptoms. They have a higher risk of recurrent stroke and may be experiencing a distinct underlying pathophysiology compared to patients from Japan. Data suggest a potential benefit with surgery if early diagnosis is made.[3]

References

  1. Wakai K, Tamakoshi A, Ikezaki K; et al. (1997). “Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey”. Clin Neurol Neurosurg. 99 Suppl 2: S1–5. doi:10.1016/S0303-8467(97)00031-0. PMID 9409395.
  2. Kuriyama S, Kusaka Y, Fujimura M; et al. (2008). “Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey”. Stroke. 39 (1): 42–7. doi:10.1161/STROKEAHA.107.490714. PMID 18048855.
  3. Hallemeier C, Rich K, Brubb R, Chicoine M, Moran C, Cross D, Zipfel G, Dacey R, Derdeyn (2006). “Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey”. Stroke. 37 (6): 1490–1496. doi:10.1161/01.STR.0000221787.70503.ca. PMID 16645133.

Template:WH Template:WS

Risk Factors

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Overview

Women have a higher risk of recurrent stroke and may be experiencing a distinct underlying pathophysiology compared to patients from Japan.

References

Template:WH Template:WS

Screening

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

References

Template:WH Template:WS

Natural History, Complications and Prognosis

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishnu Vardhan Serla M.B.B.S. [2]

Natural History

The natural history of this disorder is not well known. Symptomatic Moyamoya disease have occurred in individuals with seemingly asymptomatic stability thought due to vascular insufficiency secondary to brain trauma which may result from axonal shearing and acceleration / deceleration injuries such as falls and/or high speed motor vehicle accidents.

Prognosis

The long term outlook for patients with treated moyamoya seems to be good. While symptoms may seem to improve almost immediately after the in-direct EDAS, EMS, and multiple burr holes surgeries, it will take probably 6–12 months before new vessels (blood supply) can develop sufficiently. With the direct STA-MCA surgery, increased blood supply is immediate. Once major strokes or bleeding take place, even with treatment, the patient may be left with permanent loss of function so it is very important to treat this condition promptly.

References

Template:WH Template:WS

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Template:Cerebrovascular diseases

de:Moyamoya id:Sindrom Moyamoya nl:Moyamoya-syndroom


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH